ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part four of a video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option. He argues that closing that gap could improve outcomes and lower long-term costs.
• In a new Q&A, E.K. Koh, chief product officer at Suvoda, argues that a trustworthy AI assistant must answer only the questions it was designed and tested to answer, and that curated clinical knowledge matters more than general-purpose flexibility in a regulated setting. When assistants move from answering questions to taking actions, he recommends confirmation before each action, auditable records, and no more authority than the user already holds.
• FDA draft guidance outlines how one biologics license application can cover multiple patient-specific gene editing product variants. Sponsors could add new variants after approval using in vitro data instead of new clinical trials, as long as they fall within predefined boundaries covering features such as guide RNA sequences and editor proteins. The guidance also addresses manufacturing, safety testing for unintended genetic changes, and product labeling, and FDA says it puts key elements of its Rare Disease Framework into practice, with public comments due November 27, 2026.

That’s all for today’s ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.